Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on July 12, 2018. The report details a corporate event occurring on the same date regarding the partial exercise of an over-allotment option in a public offering.
Key Financial Metrics
- Shares Issued: 1,500,000 shares of common stock issued to the underwriter (A.G.P./Alliance Global Partners).
- Offering Price: $0.90 per share.
- Total Shares Sold: 5,850,000 shares (cumulative after partial exercise).
- Gross Proceeds: Approximately $17,350,000.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes
The filing reports an increase in the total number of shares sold in the public offering and a corresponding increase in gross proceeds due to the underwriter's partial exercise of the over-allotment option. No prior comparable period financial data (revenue, profit, or cash flow) is provided in this specific filing.
Outlook and Management Commentary
Management intends to utilize the proceeds from the over-allotment for working capital and general corporate purposes. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the immediate transaction details.
Investor Verification Checklist
- Verify the total outstanding share count post-issuance to assess dilution impact.
- Confirm the final closing of the public offering and the total net proceeds after deducting underwriting fees and expenses.
- Review the company's cash position and burn rate to evaluate the sufficiency of the $17.35 million in gross proceeds for stated working capital needs.